文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19急性呼吸窘迫综合征患者固有免疫失控与适应性免疫受损

Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01
一句话结论COVID-19 ARDS患者存在深度持续性淋巴细胞减少和高趋化因子表达,第28天死亡率高于非COVID-19 ARDS,血清CXCL10/IP-10和GM-CSF升高及鼻咽病毒载量高与第28天死亡相关。

这项前瞻性单中心观察性研究纳入RT-PCR确诊SARS-CoV-2感染并符合ARDS的患者38例,与非COVID-19 ARDS患者36例对照,比较免疫病理并寻找与死亡相关的生物标志物。两组年龄、性别、SOFA和SAPS II评分无显著差异,但COVID-19组第28天死亡率更高(34% vs 11%,P=0.030)。COVID-19组表现为深度持续性CD4+、CD8+和B淋巴细胞减少,单核细胞HLA-DR表达升高,血清EGF、GM-CSF、IL-10、CCL2/MCP-1、CCL3/MIP-1a、CXCL10/IP-10、CCL5/RANTES和CCL20/MIP-3a浓度升高。校正年龄和SOFA后,第28天死亡的COVID-19患者血清CXCL10/IP-10(P=0.047)和GM-CSF(P=0.050)更高,鼻咽RT-PCR循环阈值更低(P=0.010)。

要点

  • COVID-19 ARDS患者第28天死亡率34%,高于非COVID-19 ARDS患者的11%(P=0.030)。
  • COVID-19 ARDS患者存在深度持续性CD4+(P=0.002)、CD8+(P<0.0001)和B细胞(P<0.0001)淋巴细胞减少。
  • COVID-19 ARDS患者单核细胞HLA-DR表达升高(P<0.001),血清GM-CSF、IL-10、CXCL10/IP-10等多种细胞因子/趋化因子浓度升高。
  • 校正年龄和SOFA后,第28天死亡的COVID-19患者血清CXCL10/IP-10(P=0.047)和GM-CSF(P=0.050)更高。
  • 校正年龄和SOFA后,第28天死亡的COVID-19患者鼻咽RT-PCR循环阈值更低(P=0.010),提示病毒载量更高。

适用人群与场景

  • 纳入RT-PCR确诊SARS-CoV-2感染且符合ARDS的免疫功能正常患者,2020年3月8日至3月30日入住ICU。
  • 对照为非COVID-19 ARDS患者。

研究设计与关键结果

  • 前瞻性观察性单中心研究,COVID-19 ARDS组38例,非COVID-19 ARDS组36例,主要临床终点为第28天死亡率。
  • 两组年龄、性别、SOFA评分和SAPS II评分无显著差异,COVID-19组第28天死亡率34% vs 非COVID-19组11%(P=0.030)。
  • COVID-19组CD4+(P=0.002)、CD8+(P<0.0001)和B细胞(P<0.0001)淋巴细胞减少,单核细胞HLA-DR表达升高(P<0.001)。
  • COVID-19组血清EGF、GM-CSF、IL-10、CCL2/MCP-1、CCL3/MIP-1a、CXCL10/IP-10、CCL5/RANTES和CCL20/MIP-3a浓度升高。
  • 校正年龄和SOFA后,第28天死亡的COVID-19患者血清CXCL10/IP-10更高(P=0.047)、GM-CSF更高(P=0.050)、鼻咽RT-PCR循环阈值更低(P=0.010)。

证据类型、等级与局限

  • 证据类型:前瞻性观察性单中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,COVID-19 ARDS患者存在深度全面淋巴细胞减少和「趋化因子特征」。
  • 作者认为,血清CXCL10/IP-10和GM-CSF升高以及鼻咽SARS-CoV-2病毒载量更高与第28天死亡率相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Uncontrolled inflammatory innate response and impaired adaptive immune response are associated with clinical severity in patients with coronavirus disease (COVID-19).Objectives: To compare the immunopathology of COVID-19 acute respiratory distress syndrome (ARDS) with that of non-COVID-19 ARDS, and to identify biomarkers associated with mortality in patients with COVID-19 ARDS.Methods: Prospective observational monocenter study. Immunocompetent patients diagnosed with RT-PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and ARDS admitted between March 8 and March 30, 2020, were included and compared with patients with non-COVID-19 ARDS. The primary clinical endpoint of the study was mortality at Day 28. Flow cytometry analyses and serum cytokine measurements were performed at Days 1-2 and 4-6 of ICU admission.Measurements and Main Results: As compared with patients with non-COVID-19 ARDS (n = 36), those with COVID-19 (n = 38) were not significantly different regarding age, sex, and Sequential Organ Failure Assessment and Simplified Acute Physiology Score II scores but exhibited a higher Day-28 mortality (34% vs. 11%, P = 0.030). Patients with COVID-19 showed profound and sustained T CD4+ (P = 0.002), CD8+ (P < 0.0001), and B (P < 0.0001) lymphopenia, higher HLA-DR expression on monocytes (P < 0.001) and higher serum concentrations of EGF (epithelial growth factor), GM-CSF, IL-10, CCL2/MCP-1, CCL3/MIP-1a, CXCL10/IP-10, CCL5/RANTES, and CCL20/MIP-3a. After adjusting on age and Sequential Organ Failure Assessment, serum CXCL10/IP-10 (P = 0.047) and GM-CSF (P = 0.050) were higher and nasopharyngeal RT-PCR cycle threshold values lower (P = 0.010) in patients with COVID-19 who were dead at Day 28.Conclusions: Profound global lymphopenia and a "chemokine signature" were observed in COVID-19 ARDS. Increased serum concentrations of CXCL10/IP-10 and GM-CSF, together with higher nasopharyngeal SARS-CoV-2 viral load, were associated with Day-28 mortality.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Hue S, Beldi-Ferchiou A, Bendib I, et al. Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2020. PMID: 32866033. doi:10.1164/rccm.202005-1885OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。